European COPD Audit Finds Big National Differences Medscape September 30, 2011 (Amsterdam, the Netherlands) — The initial results of the largest-ever prospective observational audit of chronic obstructive pulmonary disease (COPD) in 13 European countries were reported here at the European Respiratory Society ... |
Novartis presents positive trial data for COPD therapy Zenopa Novartis has published positive data from new phase III clinical trials of its developmental chronic obstructive pulmonary disease (COPD) drug NVA237. Results from the Glow1 and Glow3 studies have shown that the once-daily glycopyrronium bromide-based ... Novartis Shares More Positive DataZacks.com all 6 news articles » |
Klein shines light on COPD Edmonton Journal Unfortunately Klein is one of more than 750000 Canadians besieged by chronic obstructive pulmonary disease (COPD), which causes the airways in his lungs to become swollen and partly blocked. COPD is a long-term disease that gets progressively worse ... EU-funded research discovered 16 new sections of the genetic code associated ...Euroalert.net all 2 news articles » |
 MedIndia | Higher Death Risk For Underweight Patients With COPD Medical News Today A new study presented at the European Respiratory Society's Annual Congress in Amsterdam, shows that underweight chronic obstructive pulmonary disease (COPD) patients have a higher risk of mortality risk. According to predictions made by The World ... COPD Uncovered: International Survey Results Highlight True Impact of Chronic ...PR Web (press release) Adverse health consequences in COPD patients with rapid decline in FEV1 ...7thSpace Interactive (press release) Screen for COPD during annual reviews, say GP specialistsGP online EurekAlert (press release) -Doctors Lounge -News-Medical.net all 22 news articles » |
Novartis Files for European Approval of COPD Agent Pharmaceutical Processing According to Novartis, the GLOW1 study met its main goal, demonstrating that NVA237 dosed once daily led to a significant improvement in lung function, as measured by FEV1, after 12 weeks in patients with moderate-to-severe COPD compared to placebo. ... COPD Sufferers Can Maintain Productive And Active Lives, Novartis Data Shows ...Medical News Today Novartis COPD drug Seebri Breezhaler filed in EuropePharma Times Novartis' Respiratory Ambitions Are On TrackSeeking Alpha Pharmaceutical Business Review all 6 news articles » |
IPCRG: Experts Call for Urgent Prioritisation of COPD Management Strategies to ... MarketWatch (press release) AMSTERDAM, Sep 28, 2011 (BUSINESS WIRE) -- 90 per cent of the 3 million annual global deaths from respiratory diseases occur in low- and middle-income countries (LMICs)(1)and by 2025, COPD is predicted to become the third cause of death in Africa, ... and more » |
 Private MD | COPD increases risk of heart disease, study finds Private MD Individuals who suffer from chronic obstructive pulmonary disease, or COPD, may benefit from talking to their doctor about cholesterol testing. A new study indicates that patients with the chronic lung condition are significantly more likely to also ... COPD Patients Have an Increased Risk of Cardiovascular DiseaseIvanhoe Early diagnosis key to controlling COPDSouthtownStar Course for people with breathing problemsThe Nelson Post Christian County Headliner News all 8 news articles » |
Roflumilast trial shows reduced exacerbations in COPD patients Pharmaceutical Business Review Pharmaceutical giant Nycomed announced that Daxas (roflumilast) aids in prevention of exacerbations in COPD patients of the 'frequent exacerbator' phenotype, as evident from new data analysis. Two one-year studies of over 1500 roflumilast-treated ... |
Early diagnosis key to controlling COPD SouthtownStar Supplied Photo Chronic obstructive pulmonary disease, commonly known as COPD, has recently become the third leading cause of death in the United States. Emphysema, chronic bronchitis and a small subset of asthmatic patients represent the categories of ... |